Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 11:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 169 matching trials from the live ClinicalTrials.gov search.
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Placebo, JNJ-31001074
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
21
States / cities
Irvine, California • Lafayette, California • San Francisco, California + 18 more
Conditions
ADHD
Interventions
NRCT-101-SR, Placebo
Drug
Lead sponsor
Neurocentria, Inc.
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Garden Grove, California • Lakeland, Florida • Maitland, Florida + 6 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Active transcranial photobiomodulation, Sham transcranial photobiomodulation
Device
Lead sponsor
Francisco Gonzalez-Lima, PhD
Other
Eligibility
18 Years to 44 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Austin, Texas
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine Hydrochloride, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
20
States / cities
Irvine, California • Gainesville, Florida • Tampa, Florida + 17 more
Conditions
ADHD
Interventions
Meditation/Relaxation Response Training
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 49 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Placebo, Ritalin LA 20 mg, Ritalin LA 30 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
21
States / cities
Little Rock, Arkansas • Beverly Hills, California • Spring Valley, California + 16 more
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Lisdexamfetamine Dimesylate 40 MG, Placebo
Drug
Lead sponsor
Gregory Fabiano
Other
Eligibility
16 Years to 25 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Centanafadine SR, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
TC-5619-238 5mg, TC-5619-238 25mg, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
14
States / cities
Beverly Hills, California • National City, California • Colorado Springs, Colorado + 9 more
Conditions
ADHD
Interventions
TC-5619-238, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
16
States / cities
Bradenton, Florida • Jacksonville, Florida • Lauderhill, Florida + 13 more
Conditions
ADHD
Interventions
Dance Exergaming, Stationary Cycling, Music Listening
Behavioral
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
18 Years to 24 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Blacksburg, Virginia
Conditions
Cerebrovascular Accident, Transient Ischemic Attack, ADHD
Interventions
atomoxetine, Stimulants, No intervention (general population)
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
72,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
ADHD
Interventions
lisdexamfetamine
Drug
Lead sponsor
Florida International University
Other
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Miami, Florida
Conditions
Adult Attention Deficit Hyperactivity Disorder
Interventions
Dasotraline, Placebo
Drug · Other
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
59
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 48 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
NS2359, Placebo
Drug
Lead sponsor
NeuroSearch A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional

Assessing Mobile Apps for Adult ADHD

NCT06256003
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
UC-A, UC-N
Device
Lead sponsor
Think Now Incorporated
Industry
Eligibility
18 Years to 50 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Berkeley, California • Los Angeles, California
Conditions
ADHD
Interventions
memantine hydrochloride
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cambridge, Massachusetts
Terminated Phase 2 Interventional Accepts healthy volunteers

Neuroimaging, Omega-3 and Reward in Adults With ADHD (NORAA) Trial

NCT02156089
Conditions
Attention Deficit Disorder, Attention Deficit Hyerpactivity Disorder
Interventions
Highly unsaturated omega-3 fatty acids
Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
ADHD
Interventions
Drug: PRC-063, PRC-063
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
12 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
30
States / cities
Los Angeles, California • National City, California • Newport Beach, California + 25 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine 80 mg/d, Placebo, OROS methylphenidate HCl 54 mg/d, JNJ-31001074 3 mg/d, JNJ-31001074 1 mg/d, JNJ-31001074 10 mg/d
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
35
States / cities
Little Rock, Arkansas • Lafayette, California • Los Alamitos, California + 32 more
Conditions
Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders
Interventions
NRP104
Drug
Lead sponsor
New River Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Adult Attention Deficit Hyperactivity Disorder
Interventions
OPC-64005, Atomoxetine, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
26
States / cities
Beverly Hills, California • Garden Grove, California • San Diego, California + 20 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Mindfulness Awareness Practices for ADHD (adapted), Services-As-Usual
Behavioral
Lead sponsor
University of Alabama, Tuscaloosa
Other
Eligibility
17 Years to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Tuscaloosa, Alabama • Spartanburg, South Carolina
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Oxytocin nasal spray, Placebo nasal spray
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts